Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes. (Record no. 14446290)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01251 a2200313 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250514165320.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 200409s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1538-7933 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1111/j.1538-7836.2004.00559.x |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Exaire, J E |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20040917 |
| 245 00 - TITLE STATEMENT | |
| Title | Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Journal of thrombosis and haemostasis : JTH |
| Date of publication, distribution, etc. | Jan 2004 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 7-9 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Journal Article; Review |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Abciximab |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Angioplasty, Balloon, Coronary |
| General subdivision | methods |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antibodies, Monoclonal |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cost-Benefit Analysis |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Immunoglobulin Fab Fragments |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Platelet Aggregation Inhibitors |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Platelet Glycoprotein GPIIb-IIIa Complex |
| General subdivision | antagonists & inhibitors |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Safety |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lincoff, A M |
| 773 0# - HOST ITEM ENTRY | |
| Title | Journal of thrombosis and haemostasis : JTH |
| Related parts | vol. 2 |
| -- | no. 1 |
| -- | p. 7-9 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1111/j.1538-7836.2004.00559.x">https://doi.org/10.1111/j.1538-7836.2004.00559.x</a> |
| Public note | Available from publisher's website |
No items available.